| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | |
|---|---|---|---|---|---|---|
ASSETS | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
111,353 | 135,089 | 130,708 | 148,500 | 170,847 | 105,219 | |
Marketable securities | ||||||
234,812 | 266,740 | 315,764 | 315,495 | 310,374 | 123,439 | |
Restricted cash | ||||||
- | - | - | - | - | 200 | |
Prepaid expenses and other current assets | ||||||
9,273 | 7,488 | 5,902 | 25,591 | 16,567 | 3,095 | |
Total current assets | ||||||
355,438 | 409,317 | 452,374 | 489,586 | 497,788 | 231,953 | |
Property and equipment, net | ||||||
5,669 | 5,425 | 5,133 | 4,814 | 4,110 | 3,193 | |
Operating lease right-of-use assets | ||||||
9,737 | 10,303 | 10,860 | 11,407 | 11,922 | - | |
Other assets | ||||||
634 | 1,559 | 1,387 | 1,367 | 2,129 | 4,273 | |
Total assets | ||||||
371,478 | 426,604 | 469,754 | 507,174 | 515,949 | 239,419 | |
LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||
Current liabilities | ||||||
Accounts payable | ||||||
2,602 | 956 | 2,555 | 3,030 | 4,548 | 2,182 | |
Accrued research and development expenses | ||||||
16,797 | 19,258 | 19,171 | 15,277 | 12,725 | 10,653 | |
Accrued expenses and other current liabilities | ||||||
8,963 | 16,709 | 11,443 | 9,204 | 7,879 | 7,568 | |
Total current liabilities | ||||||
28,362 | 36,923 | 33,169 | 27,511 | 25,152 | 20,403 | |
Long-term debt | ||||||
28,548 | 28,459 | 28,370 | 28,281 | - | - | |
Operating lease liabilities - long-term | ||||||
8,105 | 8,737 | 9,342 | 9,938 | 10,537 | - | |
Accrued expenses - long-term | ||||||
- | - | - | - | - | 718 | |
Total liabilities | ||||||
65,015 | 74,119 | 70,881 | 65,730 | 35,689 | 21,121 | |
Stockholders' equity | ||||||
Common stock, $0.0001 par value; 700,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 66,338,201 shares issued and 62,094,312 shares outstanding as of March 31, 2020, and 66,284,003 shares issued and 61,635,477 shares outstanding as of December 31, 2019 | ||||||
7 | 7 | 7 | 7 | 7 | 2 | |
Additional paid-in capital | ||||||
695,205 | 686,390 | 678,010 | 671,913 | 666,648 | 33,853 | |
Accumulated deficit | ||||||
-388,244 | -334,170 | -279,472 | -230,972 | -186,474 | -153,863 | |
Accumulated other comprehensive income (loss) | ||||||
-505 | 258 | 328 | 496 | 79 | -61 | |
Total stockholders' equity | ||||||
306,463 | 352,485 | 398,873 | 441,444 | 480,260 | -120,069 | |
Total liabilities and stockholders' equity | ||||||
371,478 | 426,604 | 469,754 | 507,174 | 515,949 | 239,419 | |
Series Seed Convertible Preferred Stock | ||||||
Convertible preferred stock, shares issued, outstanding, and liquidation preference | ||||||
- | - | 0 | 0 | - | 29,200 | |
Series A Convertible Preferred Stock | ||||||
Convertible preferred stock, shares issued, outstanding, and liquidation preference | ||||||
- | - | 0 | 0 | - | 79,615 | |
Series B Convertible Preferred Stock | ||||||
Convertible preferred stock, shares issued, outstanding, and liquidation preference | ||||||
- | - | 0 | 0 | - | 229,552 | |